World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
83
Citations
25097
World Ranking
3491
National Ranking
1753

Medicine

D-Index
85
Citations
25476
World Ranking
14651
National Ranking
7414

Don L. Gibbons publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Don L. Gibbons sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 1,033 publications — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Don L. Gibbons D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Don L. Gibbons sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 83 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Don L. Gibbons is affiliated with The University of Texas MD Anderson Cancer Center in the United States and has an extensive body of research focused primarily on medicine, with a significant emphasis on oncology and related biomedical fields. Their published works demonstrate a multidisciplinary approach covering biochemistry, genetics, molecular biology, pulmonary and respiratory medicine, and immunology.

The scientist's research spans multiple subfields including oncology, pulmonary and respiratory medicine, molecular biology, immunology, and cancer research. The main topics addressed relate deeply to cancer immunotherapy and biomarkers, lung cancer treatments and mutations, cancer genomics and diagnostics, as well as lung cancer diagnosis and treatment. Additional areas of focus include lung cancer research studies, radiomics and machine learning in medical imaging, and immune responses relevant to immunotherapy.

Frequent publication venues for Don L. Gibbons include:

  • Cancer Research
  • Journal of Thoracic Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • Nature Communications

Among notable recent papers by Don L. Gibbons are:

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion, 2020, Nature Communications
  • The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1, 2021, Cancer Cell
  • Deep learning-based prediction of the T cell receptor-antigen binding specificity, 2021, Nature Machine Intelligence
  • Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer, 2021, Journal for ImmunoTherapy of Cancer

Don L. Gibbons has collaborated extensively with several frequent co-authors, including John V. Heymach, Jianjun Zhang, Tina Cascone, Ignacio I. Wistuba, and J. Jack Lee. These collaborations reflect a strong network within cancer research and clinical oncology communities.

Best Publications

  • Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

    Daniel R. Gomez;Chad Tang;Jianjun Zhang;George R. Blumenschein

  • Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez

  • Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

    Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

    Triparna Sen;B. Leticia Rodriguez;Limo Chen;Carminia Della Corte

  • Clinical trials for stem cell therapies.

    Alan Trounson;Rahul G Thakar;Geoff Lomax;Don Gibbons

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

    Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  • Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

    Don L. Gibbons;Wei Lin;Chad J. Creighton;Zain H. Rizvi

  • Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

    Vince D. Cataldo;Don Lynn Gibbons;Román Pérez-Soler;Alfonso Quintás-Cardama

  • Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

    Yanyan Lou;Lixia Diao;Edwin Roger Parra Cuentas;Warren L. Denning

  • Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus.

    Don L. Gibbons;Don L. Gibbons;Marie Christine Vaney;Alain Roussel;Armelle Vigouroux

  • A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

    Milena P. Mak;Milena P. Mak;Pan Tong;Lixia Diao;Robert J. Cardnell

  • CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-l1 blockade

    Limo Chen;Lixia Diao;Yongbin Yang;Xiaohui Yi

  • Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.

    David H. Peng;Bertha Leticia Rodriguez;Lixia Diao;Limo Chen

  • Smoking, p53 Mutation, and Lung Cancer

    Don Lynn Gibbons;Lauren Averett Byers;Jonathan M Kurie

  • Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.

    Edwin R. Parra;Naohiro Uraoka;Mei Jiang;Pamela Cook

  • miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1

    Jonathon D. Roybal;Yi Zang;Young Ho Ahn;Yanan Yang

  • The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200–dependent pathway in mice

    Yanan Yang;Young Ho Ahn;Don L. Gibbons;Yi Zang

  • The fibrotic tumor stroma

    Mitsuo Yamauchi;Thomas H. Barker;Don L. Gibbons;Jonathan M. Kurie

  • TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

    Alexandre Reuben;Rachel Gittelman;Jianjun Gao;Jiexin Zhang

  • Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

    C. Allison Stewart;Pan Tong;Robert J. Cardnell;Triparna Sen

Frequent Co-Authors

John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Carmen Behrens
Carmen Behrens The University of Texas MD Anderson Cancer Center
Jing Wang
Jing Wang The University of Texas MD Anderson Cancer Center
Lixia Diao
Lixia Diao The University of Texas MD Anderson Cancer Center
Chad J. Creighton
Chad J. Creighton Baylor College of Medicine
Jonathan M. Kurie
Jonathan M. Kurie The University of Texas MD Anderson Cancer Center
Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring advanced careers beyond undergraduate studies in Biology or Biochemistry, a range of online degrees are available to help you specialize and expand your expertise. Many students pursue fields related to healthcare administration, pharmacy, or advanced clinical practice.

Those interested in leadership can consider the number of cahme accredited mha programs that offer quality education in healthcare management through flexible online study. For clinical roles, exploring the best online dnp programs—some of which do not require on-campus clinical hours—can be an excellent next step for nurses aiming for the highest levels of practice.

If you are interested in management and research, pursuing a phd in healthcare administration online may be ideal for building skills in policy, leadership, or organizational change. Students considering pharmaceutical sciences can advance their training with an online pharmd, preparing for critical roles in research, clinical pharmacy, or drug development.

These degree pathways can open doors to specialized, high-impact careers while offering the flexibility needed by today’s students and professionals.

Best Scientists Citing Don L. Gibbons

Trending Scientists

Recently Published Articles